Literature DB >> 6138793

Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.

J G Csernansky, J Kaplan, C A Holman, L E Hollister.   

Abstract

The authors measured serum neuroleptic activity and serum prolactin levels in 26 schizophrenic outpatients on prolonged neuroleptic therapy. Of the 24 patients, 11 had moderate to severe tardive dyskinesia, as assessed by the Abnormal Involuntary Movement Scale (AIMS). AIMS scores were positively correlated with age, duration of illness, and negative schizophrenic symptoms, but not with variables of neuroleptic exposure, current serum levels of neuroleptic activity, or serum prolactin levels. Neuroleptic activity and prolactin levels were positively correlated, and both variables also correlated with the current daily dose of neuroleptics.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138793     DOI: 10.1007/bf00429003

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  Serum prolactin and clinical state during neuroleptic treatment and withdrawal.

Authors:  T P Laughren; W A Brown; B W Williams
Journal:  Am J Psychiatry       Date:  1979-01       Impact factor: 18.112

2.  A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood.

Authors:  I Creese; S H Snyder
Journal:  Nature       Date:  1977-11-10       Impact factor: 49.962

3.  Drug variables in the etiology of tardive dyskinesia application of discriminant function analysis.

Authors:  G Gardos; J O Cole; R A La Brie
Journal:  Prog Neuropsychopharmacol       Date:  1977

4.  Overview: public health issues in tardive dyskinesia.

Authors:  G Gardos; J O Cole
Journal:  Am J Psychiatry       Date:  1980-07       Impact factor: 18.112

Review 5.  Molecular pathology of schizophrenia: more than one disease process?

Authors:  T J Crow
Journal:  Br Med J       Date:  1980-01-12

6.  The effect of neuroleptics on serum prolactin in schizophrenic patients.

Authors:  H Y Meltzer; V S Fang
Journal:  Arch Gen Psychiatry       Date:  1976-03

7.  A biochemical study of tardive dyskinesia in young male patients.

Authors:  D V Jeste; L E DeLisi; S Zalcman; C D Wise; B H Phelps; J E Rosenblatt; S G Potkin; T P Bridge; R J Wyatt
Journal:  Psychiatry Res       Date:  1981-06       Impact factor: 3.222

8.  Fluphenazine decanoate and tardive dyskinesia: a possible association.

Authors:  J G Csernansky; K Grabowski; J Cervantes; J Kaplan; J A Yesavage
Journal:  Am J Psychiatry       Date:  1981-10       Impact factor: 18.112

9.  Neocortical cholinergic neurons in elderly people.

Authors:  P White; C R Hiley; M J Goodhardt; L H Carrasco; J P Keet; I E Williams; D M Bowen
Journal:  Lancet       Date:  1977-03-26       Impact factor: 79.321

10.  Neuroleptic plasma levels and tardive dyskinesia: a possible link?

Authors:  H A Nasrallah
Journal:  Schizophr Bull       Date:  1980       Impact factor: 9.306

View more
  3 in total

Review 1.  Effect of neuroleptics on positive and negative symptoms and the deficit state.

Authors:  J Angst; H H Stassen; B Woggon
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 2.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

3.  A cell membrane correlate of tardive dyskinesia in patients treated with phenothiazines.

Authors:  G S Zubenko; B M Cohen
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.